OptionsHouse

Options Trading News

February 7, 2014  Fri 9:34 AM CT

CYTR: SEE CHART GET CHAIN FIND STRATEGIES
CytRx surged on promising cancer-drug data in December, and now traders are placing a vote of confidence in the name.

optionMONSTER's marker scanners detected the sale of 5,000 March 5 puts for $0.25. Volume was more than 7 times previous open interest, which indicates a new position was implemented.

The investor is now on the hook to buy shares for $5 if they're below that level on expiration six weeks from now. Above it, they'll keep the premium as profit. (See our Education section for more on how to make money selling puts.)

CYTR is up 1.66 percent to $6.75 in morning trading. It announced on Dec. 11 that a phase II trial showed its aldoxorubicin drug was twice as effective as traditional chemotherapy in the treatment of soft-tissue sarcoma. The stock more than tripled by late January but has been pulling back since.

Total option volume is almost 3 times greater than average so far today.
Share this article with your friends


OptionsHouse

Premium Services

Archived Webinar

Education & Strategy

Options Academy: Ron's Risk Calculation--A Real Life Example

It is rare that I get a chance to give a real-life, real-time example in my articles that the readers were not only following but were actually involved in at the time the event is happening. Well, that is where we are right now in our QQQ trade from last week. Let's recap the trade itself.

View more education articles »